Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?

The effect of placebo observed in schizophrenia clinical trials represents a growing problem that interferes with signal detection for treatments, increases costs of development, discourages investment in schizophrenia research and delays the introduction of new treatments. This paper seeks to clarify key issues related to this problem and identify… CONTINUE READING